ConditionsArtificial Intelligence (AI)Artificial Intelligence (AI) in DiagnosisHypertension, Pulmonary
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50-85
SponsorNational Defense Medical Center, Taiwan
About this trial
This study aims to validate the use of an artificial intelligence-enabled electrocardiogram (AI-ECG) to screen for elevated PAP. We hypothesize that the AI-ECG model can early identify patients with pulmonary hypertension in high-risk patients, prompting further evaluation through echocardiography, potentially resulting in improving cardiovascular outcomes.
Eligibility criteria
Qualifiers
Men or women, ≥ 50 to 85 years of age
At least one 12-lead ECG within 3 months
Disqualifiers
A diagnosis of PH WHO Groups 1, 2, 3, 4, or 5
A diagnosis of hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, cardiac amyloidosis, or infiltrative cardiomyopathy
Prior heart, lung, or heart-lung transplants
Any systolic pulmonary artery pressure >50 mmHg by echocardiography before
Trial design
Treatments tested in this trial
- AI-ECG Guidance
Treatment groups
8,666 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov